Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Descriptive statistics of the study population’s baseline and follow-up characteristics by mortality outcome are described in Table 1.Baseline characteristics and follow-up differences by mortality outcomeOverallSurvivorsNon-survivorsP value*N (%)2044 (100.00)755 (36.94)1289 (63.06)Age in years54.33 [48.92, 54.50]54.17 [48.08, 54.42]54.42 [54.25, 54.75] < 0.001BMI (column %) < 0.001 ≤ 25647 (31.65)293 (38.81)354 (27.46) (25, 27.5]634 (31.02)241 (31.92)393 (30.49) (27.5, 30]414 (20.25)128 (16.95)286 (22.19) (30, 32.5]218 (10.67)64 (8.48)154 (11.95) > 32.5131 (6.41)29 (3.84)102 (7.91)Smoking status (column %) < 0.001 Never smoker587 (28.72)312 (41.32)275 (21.33) Previous smoker748 (36.59)272 (36.03)476 (36.93) Current smoker709 (34.69)171 (22.65)538 (41.74)Hypertension (%)1216 (59.49)380 (50.33)836 (64.86) < 0.001 Vitamin D deficiency** (%)488 (23.87)151 (20.00)337 (26.14)0.002 DM (column %)123 (6.02)18 (2.38)105 (8.15) < 0.001 eGFR in ml/min/1.73 m285.99 [77.25, 96.77]84.86 [76.93, 95.36]86.34 [77.50, 96.89]0.072 RHF (column %)113 (5.53)20 (2.65)93 (7.21) < 0.001 Follow-up DM (column %)288 (14.09)87 (11.52)201 (15.59)0.013 Follow-up in years27.84 [18.61, 31.24]31.69 [30.24, 32.89]21.62 [13.17, 26.93] < 0.001 Age of death in years78.79 [72.12, 85.05]84.33 [78.48, 87.74]75.33 [67.52, 82.21] < 0.001Characteristics concern variables measured at baseline, unless otherwise indicated.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Study participants were examined by a physician and a nurse who measured the men’s height, weight, and blood pressure, interviewed them and collected blood samples from them [].

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The association between renal hyperfiltration and mortality is not mediated by diabetes mellitus

Study design awaiting verification · International Urology and Nephrology · 2023

Original publication title

The association between renal hyperfiltration and mortality is not mediated by diabetes mellitus

Mounir Ould Setti; Ari Voutilainen; Leo Niskanen; Tomi-Pekka Tuomainen

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

An association between RHF and mortality risk, independent of DM, was established. RHF should be considered, managed, and followed-up as a mortality-associated condition, regardless of the status of DM. We suggest clinicians to consider including RHF screening in routine clinical care, especially diabetic care.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Renal hyperfiltration (RHF), recently established as a risk factor for mortality, is linked to current and subsequent diabetes mellitus (DM). DM could be seen as a mediator in the pathway between RHF and mortality. However, the mediating role of DM in the relationship between RHF and mortality is unclear.

Source: Background

Abstract: Methods and results

Based on a cohort of 2682 Finnish men from the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD) followed-up for 35 years, we evaluated the association between RHF and mortality, with DM as a mediator, following two methods: a classic mediation analysis approach, using Cox regression, and a counterfactual framework for mediation analysis, using g-computation, Cox regression, and logistic regression. RHF is associated with an increased risk of mortality. This association was not mediated by DM. Under a counterfactual framework and on a hazard ratio scale, RHF association with mortality had a total effect of 1.54 (95% confidence interval, 1.26 to 1.98) and a controlled direct effect of 1.66 (1.34 to 2.16).

Source: Methods and results

Abstract: Conclusion

An association between RHF and mortality risk, independent of DM, was established. RHF should be considered, managed, and followed-up as a mortality-associated condition, regardless of the status of DM. We suggest clinicians to consider including RHF screening in routine clinical care, especially diabetic care.

Source: Conclusion
Authors’ abstract

Background

Renal hyperfiltration (RHF), recently established as a risk factor for mortality, is linked to current and subsequent diabetes mellitus (DM). DM could be seen as a mediator in the pathway between RHF and mortality. However, the mediating role of DM in the relationship between RHF and mortality is unclear.

Methods and results

Based on a cohort of 2682 Finnish men from the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD) followed-up for 35 years, we evaluated the association between RHF and mortality, with DM as a mediator, following two methods: a classic mediation analysis approach, using Cox regression, and a counterfactual framework for mediation analysis, using g-computation, Cox regression, and logistic regression. RHF is associated with an increased risk of mortality. This association was not mediated by DM. Under a counterfactual framework and on a hazard ratio scale, RHF association with mortality had a total effect of 1.54 (95% confidence interval, 1.26 to 1.98) and a controlled direct effect of 1.66 (1.34 to 2.16).

Conclusion

An association between RHF and mortality risk, independent of DM, was established. RHF should be considered, managed, and followed-up as a mortality-associated condition, regardless of the status of DM. We suggest clinicians to consider including RHF screening in routine clinical care, especially diabetic care.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11255-023-03562-9.

Publication and source details

Original title: The association between renal hyperfiltration and mortality is not mediated by diabetes mellitus

Mounir Ould Setti; Ari Voutilainen; Leo Niskanen; Tomi-Pekka Tuomainen

International Urology and Nephrology · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/100010133Aarne Koskelon Säätiöhttp://dx.doi.org/10.13039/501100007361Aarne ja Aili Turusen SäätiöUniversity of Eastern Finland (UEF) including Kuopio University Hospital

Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T20:01:58.552279+00:00

DOI: 10.1007/s11255-023-03562-9 · PMC10499930